Welcome to our dedicated page for Nasus Pharma Ltd. news (Ticker: NSRX), a resource for investors and traders seeking the latest updates and insights on Nasus Pharma Ltd. stock.
Nasus Pharma Ltd. (NSRX) is a clinical-stage pharmaceutical company whose news flow centers on the development of intranasal powder products for acute and emergency medical conditions. As a NYSE American–listed issuer and foreign private filer, the company regularly releases updates that are of interest to investors following emerging healthcare and drug delivery platforms.
News about Nasus Pharma frequently highlights progress in its lead program, NS002, an investigational intranasal epinephrine powder formulation being developed as a needle-free alternative to epinephrine autoinjectors for anaphylaxis. Coverage includes early clinical trial results, regulatory milestones such as Health Canada authorization for a Phase 2 study, and announcements related to dosing of participants and study design details.
Company press releases also address corporate and capital markets events. These include the pricing and closing of its initial public offering, the approval and commencement of trading of its ordinary shares on the NYSE American under the symbol NSRX, and ceremonial milestones such as ringing the closing bell at the New York Stock Exchange. Such items provide context on Nasus Pharma’s transition to the public markets and its stated use of proceeds to advance the intranasal epinephrine program and general corporate activities.
In addition, Nasus Pharma issues news on strategic collaborations and leadership changes. Announcements have described expanded agreements with Aptar France S.A.S. and AptarGroup, Inc. to support development and planned commercialization of NS002 through device technology, development services, and supply arrangements. Leadership updates, such as the appointment of an Executive Vice President and Chief Financial Officer, are also disclosed, along with shareholder communications like the CEO’s letter outlining clinical, regulatory, and corporate priorities.
Investors and observers who follow NSRX news can use this page to review company press releases and related coverage that track Nasus Pharma’s clinical development, regulatory interactions, collaborations, governance developments, and capital markets activities over time.
Nasus Pharma (NYSE: NSRX) announced management will present at three investor conferences in late February and March 2026, with CEO Dan Teleman as the company speaker.
Events: Oppenheimer Healthcare Life Sciences (Feb 25, virtual), BIO Investment & Growth Summit (Mar 2, Miami), Citizens Life Sciences (Mar 11, Miami). Management is available for one-on-one meetings.
Nasus Pharma (NYSE: NSRX) will present data at AAAAI 2026 (Feb 27–Mar 2) on NS002, an investigational intranasal epinephrine powder. Two posters on March 1, 2026 (9:45–10:45 AM) report higher nasal deposition versus liquid spray and stability through three freeze–thaw cycles.
The presentations emphasize potential for faster epinephrine absorption and robust formulation stability for a needle‑free anaphylaxis treatment option.
Nasus Pharma (NYSE: NSRX) closed a private placement raising approximately $15.0 million gross on Feb 13, 2026. The company sold 2,695,425 ordinary shares and warrants at a combined price of $5.565 per share and warrant.
Warrants are immediately exercisable at $6.53, expire in two years or 30 trading days after top-line pivotal NS002 results. Proceeds will fund the NS002 pivotal program, other first-in-human studies, and working capital. A registration rights agreement requires resale registration with the SEC.
Nasus Pharma (NYSE: NSRX) announced a private placement of ordinary shares and warrants to raise approximately $15.0 million gross, expected to close on or about February 12, 2026, subject to customary conditions.
The company will sell 2,695,425 ordinary shares with accompanying warrants exercisable at $6.53 per share, immediately exercisable and expiring two years from issuance or 30 trading days after top-line NS002 pivotal results. Proceeds will fund the NS002 pivotal study, first-in-human studies for other programs, and working capital.
Nasus Pharma (NYSE: NSRX) reported positive interim Phase 2 results for NS002, an intranasal epinephrine powder. The open-label study enrolled 50 healthy adults with allergic rhinitis. Key pharmacokinetic advantages versus intramuscular EpiPen®: Cmax 655 pg/ml vs 548 pg/ml, Tmax 10.8 min vs 15 min, and 91% vs 67% of participants reached the 100 pg/ml plasma threshold at 5 minutes. Early exposure (AUC 0–10 min) was 55 h*pg/ml vs 32 h*pg/ml. Repeat dosing with or without nasal allergic challenge showed consistent PK benefits. Safety: NS002 was well-tolerated with no serious adverse events and mostly mild, local TEAEs. Full Phase 2 results expected by end of Q1 2026; pivotal study planned for Q4 2026.
Nasus Pharma (NYSE: NSRX) issued a 2025 shareholder letter outlining clinical and corporate milestones. The company completed an IPO in August 2025, raising $10 million in gross proceeds, and described progress advancing NS002, an investigational intranasal epinephrine powder based on its proprietary Nasax technology.
Key 2025 developments include expanded collaboration agreements with Aptar, Health Canada authorization to start a Phase 2 trial, and dosing of the first patient in October 2025. Near-term milestones include an interim analysis expected early Q1 2026 and a topline Phase 2 readout planned for end of Q1 2026, with IND, pivotal, and pediatric study initiations targeted in Q3–Q4 2026.
Nasus Pharma (NYSE: NSRX) announced the appointment of Eyal Rubin as Executive Vice President and Chief Financial Officer effective Nov 20, 2025. Rubin brings more than two decades of financial leadership in biotechnology and pharma and will lead corporate finance, financial planning, capital strategy, and investor relations as Nasus advances its intranasal therapeutic pipeline toward clinical and commercial milestones.
Rubin previously served as CFO at Protalix BioTherapeutics and BrainStorm Cell Therapeutics and held treasury leadership at Teva. He holds a BA in Business Management and an MBA in Accounting and Finance, both summa cum laude. Company leaders said Rubin’s capital markets experience will support Nasus’s growth phase.
Nasus Pharma (NYSE: NSRX) received a No-Objection Letter from Health Canada on Nov 6, 2025, clearing the company to proceed with a planned Phase 2 clinical study of NS002, an investigational intranasal epinephrine powder for anaphylaxis.
The authorization confirms acceptability of the proposed trial design, provided safety data, and manufacturing information, and enables Nasus to advance toward initiating the Phase 2 study using its proprietary Nasax technology.
Nasus Pharma (NYSE: NSRX) announced on October 8, 2025 expanded agreements with Aptar France and AptarGroup to support development and planned commercialization of NS002, an intranasal powder epinephrine candidate.
The collaboration secures a commercially proven Unit Dose System technology, access to Aptar's manufacturing, supply‑chain and technical expertise, and establishes a framework to support regulatory submissions to the FDA and EMA, aiming to accelerate NS002's path to market and reduce development risk.
Nasus Pharma (NYSE:NSRX), a clinical-stage pharmaceutical company specializing in intranasal emergency medical treatments, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The virtual presentation will be delivered by CEO Dan Teleman on September 5, 2025, from 7:00-7:30 AM ET.
The company will also be available for one-on-one meetings with investors during the conference, which can be arranged through H.C. Wainwright representatives.